Our cell data indicated that at 50 μmol/L, GSK-7975A had no loss of effect, and the concentration of free compound in vivo was significantly lower.
Interestingly, both human and cell data indicate that signalling through the MEK-ERK module itself may actually be reduced through a combination of down regulation of MEK and up-regulation of inhibitors of ERK.
In the human population data presented here, the association of PFOS concentration with increasing trans-aminase is almost as prominent as the association for PFOA, and human laboratory cell data indicate relatively lower response of liver cells to PFOS than to PFOA (Wolf et al. 2008).
Despite these inhibitory activities against recombinant AKR1C3 protein in biochemical assays, our in vitro cell data indicates that, at least in AML and CLL, a selective AKR1C3 agent has no or little anti-neoplastic activity, as none of the inhibitors reduced cell proliferation, increased differentiation or induced apoptosis in our cell models.
While primitive cancer cells proliferate with a higher rate than healthy cells, data indicate that they can still undergo quiescence, both during tumor growth and during treatment.
The single-cell data indicated that the cytoplasmic accumulation of p53, which may be proportional to the cytoplasmic pro-apoptotic activity of p53, was modulated by the bimodal switch of p53 dynamics as a function of DNA-damage strength.
We had previously shown that the gCSCs induced regulatory T cells [3]; however, during blocking experiments of TGF-β, we could not completely ablate the induction of regulatory T cells (unpublished data) indicating that other cytokines had a role in triggering the formation of regulatory T cells.
The RTCA and quantification of cell area data indicate that cells expressing WT-, Y1065F-, and Y1065A vinculin behave similarly with respect to cell spreading.
Cells pertaining to this exposure group demonstrated cell cycle progression data indicating significant apoptosis induction.
